Dimerix Limited

ASX:DXB.AX

0.41 (AUD) • At close September 16, 2024
Bedrijfsnaam Dimerix Limited
Symbool DXB.AX
Munteenheid AUD
Prijs 0.405
Beurswaarde 225,594,720
Dividendpercentage 0%
52-weken bereik 0.061 - 0.665
Industrie Biotechnology
Sector Healthcare
CEO Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D.
Website https://dimerix.com

An error occurred while fetching data.

Over Dimerix Limited

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive

Vergelijkbare Aandelen

Pharmaxis Ltd logo

Pharmaxis Ltd

PXS.AX

0.028 AUD

Imagion Biosystems Limited logo

Imagion Biosystems Limited

IBX.AX

0.023 AUD

Patrys Limited logo

Patrys Limited

PAB.AX

0.007 AUD

PainChek Limited logo

PainChek Limited

PCK.AX

0.032 AUD

Vectus Biosystems Limited logo

Vectus Biosystems Limited

VBS.AX

0.08 AUD

Imricor Medical Systems, Inc. logo

Imricor Medical Systems, Inc.

IMR.AX

0.52 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)